These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years. Kontny NE, Würthwein G, Joachim B, Boddy AV, Krischke M, Fuhr U, Thompson PA, Jörger M, Schellens JH, Hempel G. Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734 [Abstract] [Full Text] [Related]
9. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, Gill MA. Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326 [Abstract] [Full Text] [Related]
10. Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. Christensson BA, Nilsson-Ehle I, Ljungberg B, Lindblad A, Malmborg AS, Hjelte L, Strandvik B. Antimicrob Agents Chemother; 1992 Nov; 36(11):2512-7. PubMed ID: 1489195 [Abstract] [Full Text] [Related]
12. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Hennig S, Wainwright CE, Bell SC, Miller H, Friberg LE, Charles BG. Clin Pharmacokinet; 2006 Nov; 45(11):1099-114. PubMed ID: 17048974 [Abstract] [Full Text] [Related]
13. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study. Hennig S, Norris R, Kirkpatrick CM. Br J Clin Pharmacol; 2008 Apr; 65(4):502-10. PubMed ID: 17995972 [Abstract] [Full Text] [Related]
14. Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): comparative pharmacokinetics and the role of therapeutic drug monitoring. Pea F, Milaneschi R, Baraldo M, Lugatti E, Talmassons G, Furlanut M. Ther Drug Monit; 2000 Aug; 22(4):386-91. PubMed ID: 10942176 [Abstract] [Full Text] [Related]
15. Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis. Illamola SM, Huynh HQ, Liu X, Bhakta ZN, Sherwin CM, Liou TG, Carveth H, Young DC. Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061295 [Abstract] [Full Text] [Related]
16. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis. Stockmann C, Sherwin CM, Zobell JT, Lubsch L, Young DC, Olson J, Noyes BE, Ampofo K, Spigarelli MG. Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677 [Abstract] [Full Text] [Related]
17. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. Anderson BJ, Pons G, Autret-Leca E, Allegaert K, Boccard E. Paediatr Anaesth; 2005 Apr; 15(4):282-92. PubMed ID: 15787918 [Abstract] [Full Text] [Related]